A Guide to Bringing a UK Biotech Company to US Public Markets
With the United States’ thriving IPO market, low volatility and large pool of investors, many U.
Why the Up-C Structure Is a Good Alternative Route to an IPO
The umbrella partnership C corporation (Up-C) structure has been a popular option for pass-through entities looking to gain access to the capital markets.
Navigating SEC Comment Letters: Non-GAAP Disclosures and Metrics
Inevitably, companies looking to go public will face the prospect of comment letters from the Securities and Exchange Commission (SEC).
The Ultimate Guide to a Life Sciences IPO
The life sciences industry is in the middle of an IPO boom, with the 10 highest-valued biotech IPOs raising $3.
Meet Kelly Provost: A Leader in CFGI’s Life Sciences Capital Markets
Kelly Provost is a leader in CFGI’s Life Sciences Capital Markets practice and has dedicated her career to supporting companies that are trying to cure diseases and save lives, making a difference in the lives of people across the world.
April Coleman: Former SEC Reviewer Spearheading CFGI’s Dedicated IPO Team
Experience is as good as gold in the accounting advisory world, and arguably no one at CFGI has spent as much time working both sides of the advisory/client aisle than Partner April Coleman.
Clene Nanomedicine Inc. Closes Business Combination with SPAC Tottenham Acquisition I Limited
CFGI’s Capital Markets team assisted Clene Nanomedicine (“Clene”) (NYSE: CLNN) with its SPAC merger with Tottenham Acquisition I Limited (“Tottenham”).
indie Semiconductor and Thunder Bridge Acquisition II, Ltd. Close Business Combination
CFGI’s Capital Markets team assisted indie Semiconductor (“indie”) (NYSE: INDI) with its SPAC merger with Thunder Bridge Acquisition II.